Abbott reports third-quarter results. Abbott Laboratories stock gains 1.88 percent

Published on 10/22/2026 at 11:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales reached USD 13.01 billion in the third quarter on October 21, 2026. Abbott Laboratories stock costs EUR 89.31 on October 22, 2026, 1.88 percent above Xetra close.

Quarterly results and guidance

Third-quarter sales reached USD 13.01 billion on October 21, 2026.
Full-year comparable sales growth guidance was set at 6.00 percent for 2026.
Abbott Laboratories stock trades at EUR 89.31 at 11:03 a.m. CEST at Lang & Schwarz on October 22, 2026, 1.88 percent above the Xetra close of October 21, 2026.
Abbott declared a quarterly dividend payable on November 16, 2026.

Bauhaus MEDTECH DIAGNOSTIK Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 Bauhaus-Poster MEDTECH DIAGNOSTIK Geometrie Primärfarben Rot Gelb Blau Schwarz Kreise Dreiecke, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) reported third-quarter sales of USD 13.013 billion on October 21, 2026, while its stock was trading at EUR 89.31 at Lang & Schwarz on October 22, 2026 at 11:03 a.m. CEST, up 1.88 percent versus the Xetra close of October 21, 2026 at EUR 87.66. According to Abbott, reported sales grew 14.50 percent and comparable sales rose 7.00 percent in the quarter.

Results reset the growth debate

The earnings mix was stronger than the headline earnings number suggests. GAAP diluted earnings per share were USD 0.53 in the third quarter, while adjusted diluted earnings per share reached USD 1.42, compared with USD 1.30 a year earlier, according to Abbott. Finance data also show third-quarter GAAP net income of USD 920.0 million and an operating margin of 10.00 percent.

The company tightened full-year 2026 adjusted diluted earnings per share guidance to USD 5.50 to USD 5.55 and projected fourth-quarter adjusted diluted earnings per share of USD 1.62 to USD 1.67. The full-year comparable sales outlook was set at 6.00 percent, a key counterweight to the 14.50 percent reported quarterly increase.

What does 7 percent growth mean?

For investors, the answer lies in the quality of expansion. Comparable sales growth was 7.00 percent in the third quarter, while adjusted earnings per share rose 9.23 percent from USD 1.30 to USD 1.42. Investing.com reported that the quarter matched the USD 1.42 earnings consensus and placed revenue at USD 13.01 billion against a USD 12.99 billion forecast on October 21, 2026.

Three dates frame the story

Abbott completed its Exact Sciences acquisition on March 23, 2026, a company release said. On September 17, 2026, the board declared a quarterly dividend of USD 0.63 per share. The October 21, 2026 results then delivered USD 13.013 billion in sales and USD 1.42 in adjusted diluted earnings per share.

Next payment date

The next substantiated date is November 16, 2026, when Abbott's quarterly dividend is payable to shareholders of record at the close of business on October 15, 2026, according to Abbott. That payment date gives the latest report a concrete shareholder timetable.

Stock price and valuation context

Abbott Laboratories has a 52-week range of EUR 70.10 to EUR 113.36 as of October 22, 2026. The current euro quote sits inside that range, leaving the earnings guidance and the contrast between reported growth and adjusted profitability as the clearest near-term reference points.

Abbott Laboratories was trading at EUR 89.31 at Lang & Schwarz on October 22, 2026 at 11:03 a.m. CEST, 1.88 percent above the Xetra close of October 21, 2026 at EUR 87.66. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.